Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome

NCT01553591 is registered in ClinicalTrials.gov with Furiex Pharmaceuticals, Inc as lead sponsor.

NCT NCT01553591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01553591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome
Lead sponsor
Furiex Pharmaceuticals, Inc
Phase
Phase 3
Overall status
Completed
Start date
May 29, 2012
Completion date
July 29, 2014
Enrollment
1,282 (actual)
Sites
283

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome